Early and long-term outcomes of heart failure in elderly persons, 2001-2005
- PMID: 19064833
- PMCID: PMC2629051
- DOI: 10.1001/archinte.168.22.2481
Early and long-term outcomes of heart failure in elderly persons, 2001-2005
Abstract
Background: The treatment of chronic heart failure has improved during the past 2 decades, but little is known about whether the improvements are reflected in trends in early and long-term mortality and hospital readmission.
Methods: In a retrospective cohort study of 2 540 838 elderly Medicare beneficiaries hospitalized with heart failure between January 1, 2001, and December 31, 2005, we examined early and long-term all-cause mortality and hospital readmission and patient- and hospital-level predictors of these outcomes.
Results: Unadjusted in-hospital mortality declined from 5.1% to 4.2% during the study (P < .001), but 30-day, 180-day, and 1-year all-cause mortality remained fairly constant at 11%, 26%, and 37%, respectively. Nearly 1 in 4 patients were readmitted within 30 days of the index hospitalization, and two-thirds were readmitted within 1 year. Controlling for patient- and hospital-level covariates, the hazard of all-cause mortality at 1 year was slightly lower in 2005 than in 2001 (hazard ratio, 0.98; 95% confidence interval, 0.97-0.99). The hazard of readmission did not decline significantly from 2001 to 2005 (hazard ratio, 0.99; 95% confidence interval, 0.98-1.00).
Conclusions: Early and long-term all-cause mortality and hospital readmission rates remain high and have improved little with time. The need to identify optimal management strategies for these clinically complex patients is urgent.
Similar articles
-
Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure.Am J Med. 2016 Nov;129(11):1178-1184. doi: 10.1016/j.amjmed.2016.06.018. Epub 2016 Jul 9. Am J Med. 2016. PMID: 27401949 Free PMC article.
-
Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure.JAMA Cardiol. 2018 Jan 1;3(1):44-53. doi: 10.1001/jamacardio.2017.4265. JAMA Cardiol. 2018. PMID: 29128869 Free PMC article.
-
Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.Am J Med. 2016 Oct;129(10):1067-73. doi: 10.1016/j.amjmed.2016.05.008. Epub 2016 Jun 2. Am J Med. 2016. PMID: 27262781 Free PMC article.
-
One- to 10-Day Versus 11- to 30-Day All-Cause Readmission and Mortality in Older Patients With Heart Failure.Am J Cardiol. 2019 Jun 1;123(11):1840-1844. doi: 10.1016/j.amjcard.2019.03.007. Epub 2019 Mar 13. Am J Cardiol. 2019. PMID: 30928031 Free PMC article.
-
Effects of Physician Volume on Readmission and Mortality in Elderly Patients with Heart Failure: Nationwide Cohort Study.Yonsei Med J. 2018 Mar;59(2):243-251. doi: 10.3349/ymj.2018.59.2.243. Yonsei Med J. 2018. PMID: 29436192 Free PMC article.
Cited by
-
Identifying Predictors of Heart Failure Readmission in Patients From a Statutory Health Insurance Database: Retrospective Machine Learning Study.JMIR Cardio. 2024 Jul 23;8:e54994. doi: 10.2196/54994. JMIR Cardio. 2024. PMID: 39042456 Free PMC article.
-
Daily Activity Lifelogs of People With Heart Failure: Observational Study.JMIR Form Res. 2024 Feb 21;8:e51248. doi: 10.2196/51248. JMIR Form Res. 2024. PMID: 38381484 Free PMC article.
-
Quality of Palliative Care Guidelines in Patients with Heart Failure: A Systematic Review of Quality Appraisal using AGREE II Instrument.Indian J Palliat Care. 2023 Jan-Mar;29(1):7-14. doi: 10.25259/IJPC_46_2022. Epub 2022 Aug 23. Indian J Palliat Care. 2023. PMID: 36846280 Free PMC article. Review.
-
Factors associated with racial differences in all-cause 30-day readmission in adults with cardiovascular disease: an observational study of a large healthcare system.BMJ Open. 2022 Nov 24;12(11):e051661. doi: 10.1136/bmjopen-2021-051661. BMJ Open. 2022. PMID: 36424114 Free PMC article.
-
Use of Digital Health Technology in Heart Failure and Diabetes: a Scoping Review.J Cardiovasc Transl Res. 2023 Jun;16(3):526-540. doi: 10.1007/s12265-022-10273-6. Epub 2022 May 31. J Cardiovasc Transl Res. 2023. PMID: 35639339 Free PMC article. Review.
References
-
- Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316(23):1429–1435. - PubMed
-
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293–302. - PubMed
-
- Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–310. - PubMed
-
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–1355. - PubMed
-
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999;353(9169):2001–2007. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
